POST-TEST

What Clinicians Want to Know: Addressing Community Oncologists' Questions About the Care of Patients with Prostate Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. **Which of the following drug types best reflects the mechanism of action of opevesostat?**
   a. Androgen receptor pathway inhibitor (ARPI)
   b. CYP11A1 inhibitor
   c. AKT inhibitor
   d. EZH2 inhibitor

2. **The ongoing Phase III EvoPAR-Prostate02 trial is evaluating the addition of saruparib to standard therapy in which of the following settings?**
   a. Taxane-pretreated metastatic castration-resistant prostate cancer (mCRPC)
   b. Previously untreated mCRPC
   c. De novo metastatic hormone-~~senstive~~ sensitive prostate cancer (mHSPC)
   d. High-risk and very high-risk localized or locally advanced prostate cancer

3. **Which of the following statements best characterizes outcomes by degree of PTEN deficiency in the Phase III CAPItello-281 study evaluating capivasertib with abiraterone/androgen deprivation therapy (ADT) versus abiraterone/ADT alone for patients with de novo PTEN-deficient mHSPC?**
   a. Higher degrees of PTEN loss appear to correlate with worse outcomes in both treatment arms
   b. Degree of PTEN loss does not appear to affect the degree of benefit with the addition of capivasertib
   c. Higher degrees of PTEN loss appear to correlate with better outcomes among patients who received the capivasertib regimen
   d. Patients were not stratified by degree of PTEN loss in the study

4. **The Phase III PSMAfore trial evaluating lutetium Lu 177 vipivotide tetraxetan versus a change of ARPI therapy for patients with taxane-naïve mCRPC yielded which of the following outcomes?**
   a. Equivalent median radiographic progression-free survival (rPFS) and improved tolerability with lutetium Lu 177 vipivotide tetraxetan
   b. A 20% improvement in median rPFS with lutetium Lu 177 vipivotide tetraxetan
   c. More than doubled median rPFS with lutetium Lu 177 vipivotide tetraxetan
   d. Inferior median rPFS with lutetium Lu 177 vipivotide tetraxetan

5. **Which of the following descriptions best characterizes the study design of the AcTFirst trial?**
   a. A Phase II study evaluating various dose levels of 225Ac-PSMA-617 for heavily pretreated mCRPC
   b. A Phase III study evaluating 225Ac-PSMA-617 versus docetaxel for patients with mCRPC who have experienced disease progression on multiple lines of ARPI therapy
   c. A Phase III study evaluating 225Ac-PSMA-617, with or without an ARPI switch, versus standard therapy for patients with mCRPC who have experienced disease progression on a prior ARPI